Olanzapine For Schizophrenia: Effectiveness And Management

Subjects with schizophrenia (n=114) who had been randomly assigned to and then discontinued perphenazine in phase 1 of the clinical antipsychotic trials of intervention. The fda has approved this medication for schizophrenia if the patient is over the age of 13 and bipolar. Olanzapine is an atypical antipsychotic reported to be effective without producing disabling extrapyramidal adverse effects associated with older, typical antipsychotic drugs. Olanzapine demonstrated significant efficacy in reducing a wide range of schizophrenia symptoms, improving clinical status, enhancing social functioning, and. Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in the treatment of some patients with first.